Mary Jane Hinrichs

Bio:

Mary Jane leads Ipsen’s Early Development organization, a global team responsible for advancing innovative therapies across oncology, rare disease, and neuroscience. Her work focuses on translating scientific discovery into medicines by integrating translational medicine, clinical pharmacology, nonclinical safety, and pharmacokinetics to support programs across the full development lifecycle—from discovery through early clinical development and into later-stage development and regulatory submission.

Over the past several years, May Jane’s team has helped build Ipsen’s early pipeline from an initial set of programs into a diversified portfolio of more than fifteen assets spanning discovery through Phase 1 across multiple therapeutic modalities. In this role, she works closely with therapeutic area leaders, commercial teams, and business development to shape development strategies, evaluate external innovation opportunities, and ensure our programs are positioned to deliver meaningful value for patients and the broader portfolio.

Before joining Ipsen, Mary Jane held development and safety leadership roles at AstraZeneca/MedImmune and served as a Pharmacology/Toxicology reviewer in the Office of Oncology Drug Products at the U.S. FDA.

She remains deeply interested in advancing innovative approaches to drug development and building collaborative organizations that translate strong science into meaningful therapies for patients.